Clareo Health | A Long-term Follow-up Study of Botulinum Toxin Type A in Patients With Overactive Bladder as a Result of Spinal Injury or Multiple Sclerosis
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Allergan
Botulinum toxin Type A 300U has been discontinued from the study. Patients remaining in the arm containing botulinum toxin Type A 300U will receive botulinum toxin Type A 200U moving forward. Also, the masking of the study is now open-label.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patient has participated in study 191622-515 or 191622-516 and the following criteria fulfilled:
* Patient completed at least 52 weeks in the preceding study.
* No longer than 6 months has elapsed since completion of the preceding study
* Patient has not received any prohibited medications during any intervening period between the preceding study and this long-term study.
You may not be if
History or evidence of pelvic or urologic abnormality.
Previous or current diagnosis of bladder or prostate cancer.
